Abstract
To the Editor: A recent Rapid Communication described an adverse association between extended pretransplant interferon-α (IFN-α) therapy and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia (CML) in chronic phase.[1][1] Although the biologic basis of the
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
